Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer

组织微阵列 CD8型 医学 免疫组织化学 PD-L1 宫颈癌 放化疗 危险系数 癌症 病理 预测标记 免疫系统 肿瘤科 免疫疗法 癌症研究 内科学 免疫学 置信区间
作者
Emeka K. Enwere,Elizabeth Kornaga,Michelle L. Dean,Theodora Koulis,Tien Phan,Maria Kalantarian,Martin Köbel,Prafull Ghatage,Anthony M. Magliocco,Susan P. Lees‐Miller,Corinne Doll
出处
期刊:Modern Pathology [Elsevier BV]
卷期号:30 (4): 577-586 被引量:161
标识
DOI:10.1038/modpathol.2016.221
摘要

Several of the cancer immunotherapies under investigation or in clinical use target the programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) signaling axis. PD-L1 expression in tumor samples has been used as a predictive marker for response to these therapeutics, and may also have independent prognostic utility when assessed along with immune cell markers. Our objectives were to assess the expression of PD-L1 in tumor specimens from a uniformly treated patient cohort with locally advanced cervical cancer, and to determine its prognostic significance along with the density of tumor-infiltrating T cells. We identified 120 patients with locally advanced cervical cancer treated with radical chemoradiotherapy, and built tissue microarrays from their formalin-fixed, paraffin-embedded pre-treatment biopsies. We used conventional brightfield and fluorescence immunohistochemistry to detect PD-L1, and quantified protein expression using both manual pathologist scoring and automated software analysis. We also evaluated the effect of PD-L1 expression in tumors, along with the presence and density of intra-tumoral CD8+ T cells, on patient survival outcomes. Approximately 96% of the tumor samples expressed PD-L1, as determined using quantitative software analysis. Neither expression of PD-L1 nor density of CD8+ T cells was associated with progression-free or overall survival. However, there was a trend towards worse progression-free survival in patients whose tumors expressed PD-L1 but lacked CD8+ T cells (hazard ratio=0.43 (0.18-1.01), P=0.053). Nevertheless, the high percentage of cervical cancer tumor samples expressing PD-L1 suggests that anti-PD-L1 or anti-PD-1 therapies are potential treatment options for this patient population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
css发布了新的文献求助10
1秒前
Ava应助年轻小之采纳,获得10
1秒前
情怀应助xueyu采纳,获得10
1秒前
慕青应助科研通管家采纳,获得30
2秒前
Jasper应助科研通管家采纳,获得10
2秒前
慕青应助科研通管家采纳,获得10
2秒前
SYLH应助科研通管家采纳,获得20
2秒前
MchemG应助科研通管家采纳,获得10
2秒前
FashionBoy应助科研通管家采纳,获得10
2秒前
MchemG应助科研通管家采纳,获得10
2秒前
MchemG应助科研通管家采纳,获得10
2秒前
MchemG应助科研通管家采纳,获得10
2秒前
Lucas应助科研通管家采纳,获得10
3秒前
SYLH应助科研通管家采纳,获得30
3秒前
科研通AI2S应助科研通管家采纳,获得10
3秒前
JJ发布了新的文献求助10
4秒前
Nugget发布了新的文献求助10
4秒前
邓紫依发布了新的文献求助10
4秒前
5秒前
5秒前
直率的问筠完成签到,获得积分10
6秒前
不发SCI不改名完成签到,获得积分10
6秒前
7秒前
8秒前
柯睿渊完成签到,获得积分10
8秒前
独特乘云完成签到,获得积分10
8秒前
贾克斯发布了新的文献求助10
8秒前
tlh完成签到 ,获得积分10
9秒前
陈彦滨完成签到 ,获得积分10
9秒前
10秒前
12秒前
12秒前
css完成签到,获得积分10
12秒前
Liufgui应助Re采纳,获得20
12秒前
Nugget完成签到,获得积分10
12秒前
yar应助潇湘雪月采纳,获得10
13秒前
宇宇发布了新的文献求助10
13秒前
shufessm完成签到,获得积分0
15秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174